0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Parkinson Disease Drug Market Research Report 2024
Published Date: February 2024
|
Report Code: QYRE-Auto-39X2260
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Parkinson Disease Drug Market Size Status and Forecast 2021 2027
BUY CHAPTERS

Global Parkinson Disease Drug Market Research Report 2024

Code: QYRE-Auto-39X2260
Report
February 2024
Pages:99
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Parkinson Disease Drug Market Size

The global Parkinson Disease Drug market was valued at US$ 5492 million in 2023 and is anticipated to reach US$ 8397.5 million by 2030, witnessing a CAGR of 6.2% during the forecast period 2024-2030.

Parkinson Disease Drug Market

Parkinson Disease Drug Market

Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement.
Global Parkinson Disease Drug key players include Merck, Akorn, GSK, Boehringer Ingelheim, Teva Pharmaceutical, etc.
This report aims to provide a comprehensive presentation of the global market for Parkinson Disease Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Parkinson Disease Drug.

Report Scope

The Parkinson Disease Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Parkinson Disease Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Parkinson Disease Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Parkinson Disease Drug Market Report

Report Metric Details
Report Name Parkinson Disease Drug Market
Accounted market size in 2023 US$ 5492 million
Forecasted market size in 2030 US$ 8397.5 million
CAGR 6.2%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Sinemet-CR
  • Trastal
  • Madopar
  • COMT Inhibitor
  • Other
Segment by Application
  • Under 40 Years Old
  • 40-65 Years Old
  • Above 65 Years Old
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, F.Hoffmann-La Roche, H.Lundbeck, Valeant, Apokyn, Orion, Stada Arzneimittel, US WorldMeds, Bausch Health
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Parkinson Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Parkinson Disease Drug Market growing?

Ans: The Parkinson Disease Drug Market witnessing a CAGR of 6.2% during the forecast period 2024-2030.

What is the Parkinson Disease Drug Market size in 2030?

Ans: The Parkinson Disease Drug Market size in 2030 will be US$ 8397.5 million.

Who are the main players in the Parkinson Disease Drug Market report?

Ans: The main players in the Parkinson Disease Drug Market are Merck, Akorn, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, F.Hoffmann-La Roche, H.Lundbeck, Valeant, Apokyn, Orion, Stada Arzneimittel, US WorldMeds, Bausch Health

What are the Application segmentation covered in the Parkinson Disease Drug Market report?

Ans: The Applications covered in the Parkinson Disease Drug Market report are Under 40 Years Old, 40-65 Years Old, Above 65 Years Old

What are the Type segmentation covered in the Parkinson Disease Drug Market report?

Ans: The Types covered in the Parkinson Disease Drug Market report are Sinemet-CR, Trastal, Madopar, COMT Inhibitor, Other

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Parkinson Disease Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Sinemet-CR
1.2.3 Trastal
1.2.4 Madopar
1.2.5 COMT Inhibitor
1.2.6 Other
1.3 Market by Application
1.3.1 Global Parkinson Disease Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Under 40 Years Old
1.3.3 40-65 Years Old
1.3.4 Above 65 Years Old
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Parkinson Disease Drug Market Perspective (2019-2030)
2.2 Parkinson Disease Drug Growth Trends by Region
2.2.1 Global Parkinson Disease Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Parkinson Disease Drug Historic Market Size by Region (2019-2024)
2.2.3 Parkinson Disease Drug Forecasted Market Size by Region (2025-2030)
2.3 Parkinson Disease Drug Market Dynamics
2.3.1 Parkinson Disease Drug Industry Trends
2.3.2 Parkinson Disease Drug Market Drivers
2.3.3 Parkinson Disease Drug Market Challenges
2.3.4 Parkinson Disease Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Parkinson Disease Drug Players by Revenue
3.1.1 Global Top Parkinson Disease Drug Players by Revenue (2019-2024)
3.1.2 Global Parkinson Disease Drug Revenue Market Share by Players (2019-2024)
3.2 Global Parkinson Disease Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Parkinson Disease Drug Revenue
3.4 Global Parkinson Disease Drug Market Concentration Ratio
3.4.1 Global Parkinson Disease Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Parkinson Disease Drug Revenue in 2023
3.5 Parkinson Disease Drug Key Players Head office and Area Served
3.6 Key Players Parkinson Disease Drug Product Solution and Service
3.7 Date of Enter into Parkinson Disease Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Parkinson Disease Drug Breakdown Data by Type
4.1 Global Parkinson Disease Drug Historic Market Size by Type (2019-2024)
4.2 Global Parkinson Disease Drug Forecasted Market Size by Type (2025-2030)
5 Parkinson Disease Drug Breakdown Data by Application
5.1 Global Parkinson Disease Drug Historic Market Size by Application (2019-2024)
5.2 Global Parkinson Disease Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Parkinson Disease Drug Market Size (2019-2030)
6.2 North America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Parkinson Disease Drug Market Size by Country (2019-2024)
6.4 North America Parkinson Disease Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Parkinson Disease Drug Market Size (2019-2030)
7.2 Europe Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Parkinson Disease Drug Market Size by Country (2019-2024)
7.4 Europe Parkinson Disease Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Parkinson Disease Drug Market Size (2019-2030)
8.2 Asia-Pacific Parkinson Disease Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Parkinson Disease Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Parkinson Disease Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Parkinson Disease Drug Market Size (2019-2030)
9.2 Latin America Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Parkinson Disease Drug Market Size by Country (2019-2024)
9.4 Latin America Parkinson Disease Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Parkinson Disease Drug Market Size (2019-2030)
10.2 Middle East & Africa Parkinson Disease Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Parkinson Disease Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Parkinson Disease Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Merck
11.1.1 Merck Company Detail
11.1.2 Merck Business Overview
11.1.3 Merck Parkinson Disease Drug Introduction
11.1.4 Merck Revenue in Parkinson Disease Drug Business (2019-2024)
11.1.5 Merck Recent Development
11.2 Akorn
11.2.1 Akorn Company Detail
11.2.2 Akorn Business Overview
11.2.3 Akorn Parkinson Disease Drug Introduction
11.2.4 Akorn Revenue in Parkinson Disease Drug Business (2019-2024)
11.2.5 Akorn Recent Development
11.3 GSK
11.3.1 GSK Company Detail
11.3.2 GSK Business Overview
11.3.3 GSK Parkinson Disease Drug Introduction
11.3.4 GSK Revenue in Parkinson Disease Drug Business (2019-2024)
11.3.5 GSK Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Parkinson Disease Drug Introduction
11.4.4 Novartis Revenue in Parkinson Disease Drug Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Detail
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Parkinson Disease Drug Introduction
11.5.4 Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2019-2024)
11.5.5 Boehringer Ingelheim Recent Development
11.6 Teva Pharmaceutical
11.6.1 Teva Pharmaceutical Company Detail
11.6.2 Teva Pharmaceutical Business Overview
11.6.3 Teva Pharmaceutical Parkinson Disease Drug Introduction
11.6.4 Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2019-2024)
11.6.5 Teva Pharmaceutical Recent Development
11.7 Abbvie
11.7.1 Abbvie Company Detail
11.7.2 Abbvie Business Overview
11.7.3 Abbvie Parkinson Disease Drug Introduction
11.7.4 Abbvie Revenue in Parkinson Disease Drug Business (2019-2024)
11.7.5 Abbvie Recent Development
11.8 Kyowa Hakko Kirin Pharma
11.8.1 Kyowa Hakko Kirin Pharma Company Detail
11.8.2 Kyowa Hakko Kirin Pharma Business Overview
11.8.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Introduction
11.8.4 Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2019-2024)
11.8.5 Kyowa Hakko Kirin Pharma Recent Development
11.9 Astellas Pharma
11.9.1 Astellas Pharma Company Detail
11.9.2 Astellas Pharma Business Overview
11.9.3 Astellas Pharma Parkinson Disease Drug Introduction
11.9.4 Astellas Pharma Revenue in Parkinson Disease Drug Business (2019-2024)
11.9.5 Astellas Pharma Recent Development
11.10 Desitin Arzneimittel
11.10.1 Desitin Arzneimittel Company Detail
11.10.2 Desitin Arzneimittel Business Overview
11.10.3 Desitin Arzneimittel Parkinson Disease Drug Introduction
11.10.4 Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2019-2024)
11.10.5 Desitin Arzneimittel Recent Development
11.11 Endo Pharmaceuticals
11.11.1 Endo Pharmaceuticals Company Detail
11.11.2 Endo Pharmaceuticals Business Overview
11.11.3 Endo Pharmaceuticals Parkinson Disease Drug Introduction
11.11.4 Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2019-2024)
11.11.5 Endo Pharmaceuticals Recent Development
11.12 F.Hoffmann-La Roche
11.12.1 F.Hoffmann-La Roche Company Detail
11.12.2 F.Hoffmann-La Roche Business Overview
11.12.3 F.Hoffmann-La Roche Parkinson Disease Drug Introduction
11.12.4 F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2019-2024)
11.12.5 F.Hoffmann-La Roche Recent Development
11.13 H.Lundbeck
11.13.1 H.Lundbeck Company Detail
11.13.2 H.Lundbeck Business Overview
11.13.3 H.Lundbeck Parkinson Disease Drug Introduction
11.13.4 H.Lundbeck Revenue in Parkinson Disease Drug Business (2019-2024)
11.13.5 H.Lundbeck Recent Development
11.14 Valeant
11.14.1 Valeant Company Detail
11.14.2 Valeant Business Overview
11.14.3 Valeant Parkinson Disease Drug Introduction
11.14.4 Valeant Revenue in Parkinson Disease Drug Business (2019-2024)
11.14.5 Valeant Recent Development
11.15 Apokyn
11.15.1 Apokyn Company Detail
11.15.2 Apokyn Business Overview
11.15.3 Apokyn Parkinson Disease Drug Introduction
11.15.4 Apokyn Revenue in Parkinson Disease Drug Business (2019-2024)
11.15.5 Apokyn Recent Development
11.16 Orion
11.16.1 Orion Company Detail
11.16.2 Orion Business Overview
11.16.3 Orion Parkinson Disease Drug Introduction
11.16.4 Orion Revenue in Parkinson Disease Drug Business (2019-2024)
11.16.5 Orion Recent Development
11.17 Stada Arzneimittel
11.17.1 Stada Arzneimittel Company Detail
11.17.2 Stada Arzneimittel Business Overview
11.17.3 Stada Arzneimittel Parkinson Disease Drug Introduction
11.17.4 Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2019-2024)
11.17.5 Stada Arzneimittel Recent Development
11.18 US WorldMeds
11.18.1 US WorldMeds Company Detail
11.18.2 US WorldMeds Business Overview
11.18.3 US WorldMeds Parkinson Disease Drug Introduction
11.18.4 US WorldMeds Revenue in Parkinson Disease Drug Business (2019-2024)
11.18.5 US WorldMeds Recent Development
11.19 Bausch Health
11.19.1 Bausch Health Company Detail
11.19.2 Bausch Health Business Overview
11.19.3 Bausch Health Parkinson Disease Drug Introduction
11.19.4 Bausch Health Revenue in Parkinson Disease Drug Business (2019-2024)
11.19.5 Bausch Health Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Parkinson Disease Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
    Table 2. Key Players of Sinemet-CR
    Table 3. Key Players of Trastal
    Table 4. Key Players of Madopar
    Table 5. Key Players of COMT Inhibitor
    Table 6. Key Players of Other
    Table 7. Global Parkinson Disease Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
    Table 8. Global Parkinson Disease Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 9. Global Parkinson Disease Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 10. Global Parkinson Disease Drug Market Share by Region (2019-2024)
    Table 11. Global Parkinson Disease Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 12. Global Parkinson Disease Drug Market Share by Region (2025-2030)
    Table 13. Parkinson Disease Drug Market Trends
    Table 14. Parkinson Disease Drug Market Drivers
    Table 15. Parkinson Disease Drug Market Challenges
    Table 16. Parkinson Disease Drug Market Restraints
    Table 17. Global Parkinson Disease Drug Revenue by Players (2019-2024) & (US$ Million)
    Table 18. Global Parkinson Disease Drug Market Share by Players (2019-2024)
    Table 19. Global Top Parkinson Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinson Disease Drug as of 2023)
    Table 20. Ranking of Global Top Parkinson Disease Drug Companies by Revenue (US$ Million) in 2023
    Table 21. Global 5 Largest Players Market Share by Parkinson Disease Drug Revenue (CR5 and HHI) & (2019-2024)
    Table 22. Key Players Headquarters and Area Served
    Table 23. Key Players Parkinson Disease Drug Product Solution and Service
    Table 24. Date of Enter into Parkinson Disease Drug Market
    Table 25. Mergers & Acquisitions, Expansion Plans
    Table 26. Global Parkinson Disease Drug Market Size by Type (2019-2024) & (US$ Million)
    Table 27. Global Parkinson Disease Drug Revenue Market Share by Type (2019-2024)
    Table 28. Global Parkinson Disease Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 29. Global Parkinson Disease Drug Revenue Market Share by Type (2025-2030)
    Table 30. Global Parkinson Disease Drug Market Size by Application (2019-2024) & (US$ Million)
    Table 31. Global Parkinson Disease Drug Revenue Market Share by Application (2019-2024)
    Table 32. Global Parkinson Disease Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 33. Global Parkinson Disease Drug Revenue Market Share by Application (2025-2030)
    Table 34. North America Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 35. North America Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 36. North America Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 37. Europe Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 38. Europe Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 39. Europe Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 40. Asia-Pacific Parkinson Disease Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 41. Asia-Pacific Parkinson Disease Drug Market Size by Region (2019-2024) & (US$ Million)
    Table 42. Asia-Pacific Parkinson Disease Drug Market Size by Region (2025-2030) & (US$ Million)
    Table 43. Latin America Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 44. Latin America Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 45. Latin America Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 46. Middle East & Africa Parkinson Disease Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 47. Middle East & Africa Parkinson Disease Drug Market Size by Country (2019-2024) & (US$ Million)
    Table 48. Middle East & Africa Parkinson Disease Drug Market Size by Country (2025-2030) & (US$ Million)
    Table 49. Merck Company Detail
    Table 50. Merck Business Overview
    Table 51. Merck Parkinson Disease Drug Product
    Table 52. Merck Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 53. Merck Recent Development
    Table 54. Akorn Company Detail
    Table 55. Akorn Business Overview
    Table 56. Akorn Parkinson Disease Drug Product
    Table 57. Akorn Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 58. Akorn Recent Development
    Table 59. GSK Company Detail
    Table 60. GSK Business Overview
    Table 61. GSK Parkinson Disease Drug Product
    Table 62. GSK Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 63. GSK Recent Development
    Table 64. Novartis Company Detail
    Table 65. Novartis Business Overview
    Table 66. Novartis Parkinson Disease Drug Product
    Table 67. Novartis Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 68. Novartis Recent Development
    Table 69. Boehringer Ingelheim Company Detail
    Table 70. Boehringer Ingelheim Business Overview
    Table 71. Boehringer Ingelheim Parkinson Disease Drug Product
    Table 72. Boehringer Ingelheim Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 73. Boehringer Ingelheim Recent Development
    Table 74. Teva Pharmaceutical Company Detail
    Table 75. Teva Pharmaceutical Business Overview
    Table 76. Teva Pharmaceutical Parkinson Disease Drug Product
    Table 77. Teva Pharmaceutical Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 78. Teva Pharmaceutical Recent Development
    Table 79. Abbvie Company Detail
    Table 80. Abbvie Business Overview
    Table 81. Abbvie Parkinson Disease Drug Product
    Table 82. Abbvie Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 83. Abbvie Recent Development
    Table 84. Kyowa Hakko Kirin Pharma Company Detail
    Table 85. Kyowa Hakko Kirin Pharma Business Overview
    Table 86. Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product
    Table 87. Kyowa Hakko Kirin Pharma Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 88. Kyowa Hakko Kirin Pharma Recent Development
    Table 89. Astellas Pharma Company Detail
    Table 90. Astellas Pharma Business Overview
    Table 91. Astellas Pharma Parkinson Disease Drug Product
    Table 92. Astellas Pharma Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 93. Astellas Pharma Recent Development
    Table 94. Desitin Arzneimittel Company Detail
    Table 95. Desitin Arzneimittel Business Overview
    Table 96. Desitin Arzneimittel Parkinson Disease Drug Product
    Table 97. Desitin Arzneimittel Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 98. Desitin Arzneimittel Recent Development
    Table 99. Endo Pharmaceuticals Company Detail
    Table 100. Endo Pharmaceuticals Business Overview
    Table 101. Endo Pharmaceuticals Parkinson Disease Drug Product
    Table 102. Endo Pharmaceuticals Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 103. Endo Pharmaceuticals Recent Development
    Table 104. F.Hoffmann-La Roche Company Detail
    Table 105. F.Hoffmann-La Roche Business Overview
    Table 106. F.Hoffmann-La Roche Parkinson Disease Drug Product
    Table 107. F.Hoffmann-La Roche Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 108. F.Hoffmann-La Roche Recent Development
    Table 109. H.Lundbeck Company Detail
    Table 110. H.Lundbeck Business Overview
    Table 111. H.Lundbeck Parkinson Disease Drug Product
    Table 112. H.Lundbeck Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 113. H.Lundbeck Recent Development
    Table 114. Valeant Company Detail
    Table 115. Valeant Business Overview
    Table 116. Valeant Parkinson Disease Drug Product
    Table 117. Valeant Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 118. Valeant Recent Development
    Table 119. Apokyn Company Detail
    Table 120. Apokyn Business Overview
    Table 121. Apokyn Parkinson Disease Drug Product
    Table 122. Apokyn Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 123. Apokyn Recent Development
    Table 124. Orion Company Detail
    Table 125. Orion Business Overview
    Table 126. Orion Parkinson Disease Drug Product
    Table 127. Orion Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 128. Orion Recent Development
    Table 129. Stada Arzneimittel Company Detail
    Table 130. Stada Arzneimittel Business Overview
    Table 131. Stada Arzneimittel Parkinson Disease Drug Product
    Table 132. Stada Arzneimittel Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 133. Stada Arzneimittel Recent Development
    Table 134. US WorldMeds Company Detail
    Table 135. US WorldMeds Business Overview
    Table 136. US WorldMeds Parkinson Disease Drug Product
    Table 137. US WorldMeds Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 138. US WorldMeds Recent Development
    Table 139. Bausch Health Company Detail
    Table 140. Bausch Health Business Overview
    Table 141. Bausch Health Parkinson Disease Drug Product
    Table 142. Bausch Health Revenue in Parkinson Disease Drug Business (2019-2024) & (US$ Million)
    Table 143. Bausch Health Recent Development
    Table 144. Research Programs/Design for This Report
    Table 145. Key Data Information from Secondary Sources
    Table 146. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Parkinson Disease Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
    Figure 2. Global Parkinson Disease Drug Market Share by Type: 2023 VS 2030
    Figure 3. Sinemet-CR Features
    Figure 4. Trastal Features
    Figure 5. Madopar Features
    Figure 6. COMT Inhibitor Features
    Figure 7. Other Features
    Figure 8. Global Parkinson Disease Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
    Figure 9. Global Parkinson Disease Drug Market Share by Application: 2023 VS 2030
    Figure 10. Under 40 Years Old Case Studies
    Figure 11. 40-65 Years Old Case Studies
    Figure 12. Above 65 Years Old Case Studies
    Figure 13. Parkinson Disease Drug Report Years Considered
    Figure 14. Global Parkinson Disease Drug Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 15. Global Parkinson Disease Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 16. Global Parkinson Disease Drug Market Share by Region: 2023 VS 2030
    Figure 17. Global Parkinson Disease Drug Market Share by Players in 2023
    Figure 18. Global Top Parkinson Disease Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Parkinson Disease Drug as of 2023)
    Figure 19. The Top 10 and 5 Players Market Share by Parkinson Disease Drug Revenue in 2023
    Figure 20. North America Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 21. North America Parkinson Disease Drug Market Share by Country (2019-2030)
    Figure 22. United States Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Canada Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 24. Europe Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 25. Europe Parkinson Disease Drug Market Share by Country (2019-2030)
    Figure 26. Germany Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 27. France Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. U.K. Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. Italy Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Russia Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Nordic Countries Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Asia-Pacific Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. Asia-Pacific Parkinson Disease Drug Market Share by Region (2019-2030)
    Figure 34. China Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 35. Japan Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 36. South Korea Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 37. Southeast Asia Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 38. India Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 39. Australia Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 40. Latin America Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. Latin America Parkinson Disease Drug Market Share by Country (2019-2030)
    Figure 42. Mexico Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Brazil Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. Middle East & Africa Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Middle East & Africa Parkinson Disease Drug Market Share by Country (2019-2030)
    Figure 46. Turkey Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 47. Saudi Arabia Parkinson Disease Drug Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 48. Merck Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 49. Akorn Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 50. GSK Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 51. Novartis Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 52. Boehringer Ingelheim Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 53. Teva Pharmaceutical Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 54. Abbvie Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 55. Kyowa Hakko Kirin Pharma Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 56. Astellas Pharma Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 57. Desitin Arzneimittel Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 58. Endo Pharmaceuticals Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 59. F.Hoffmann-La Roche Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 60. H.Lundbeck Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 61. Valeant Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 62. Apokyn Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 63. Orion Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 64. Stada Arzneimittel Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 65. US WorldMeds Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 66. Bausch Health Revenue Growth Rate in Parkinson Disease Drug Business (2019-2024)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS